ASCO Annual Meeting | Conference

Asciminib Bests Standard-of-Care TKIs in Ph+ CML

May 31st 2024

Treatment with asciminib led to a superior 48-week major molecular response rate vs investigator-selected TKIs in patients with Ph-positive chronic phase chronic myeloid leukemia.

Lorlatinib Yields Longest Reported PFS in Advanced ALK+ NSCLC

May 31st 2024

Lorlatinib extended PFS and improved time to intracranial progression vs crizotinib in patients with ALK-positive non–small cell lung cancer.

Dr Pal Previews ASCO 2024 Data in Renal Cell Carcinoma

May 23rd 2024

Sumanta Kumar Pal, MD, FASCO, discusses key biomarker analyses in renal cell carcinoma that will be presented at the 2024 ASCO Annual Meeting.

Prospective Data Reveal Most Young Survivors of Breast Cancer Could Successfully Give Birth

May 23rd 2024

Most women who attempted to conceive following treatment for stage I to III breast cancer were able to become pregnant at least once.

HPV Vaccinations Associated With Lower Rates of HPV-Caused Cancers in Patients Under 40 Years of Age

May 23rd 2024

Patients under the age of 40 who received HPV vaccines were associated with lower rates of HPV-related cancer vs unvaccinated patients.

AI Virtual Navigation May Reengage Patients to Undergo Missed Colonoscopies

May 23rd 2024

An artificial intelligence-based navigation tool may be used to call patients who previously missed their colonoscopy appointment with the goal that they will reschedule and attend the new appointment.

Long-Term Findings Clarify Role of Estrogen Therapy on Ovarian/Endometrial Cancer Incidence

May 23rd 2024

Treatment with CEE alone was associated with increased ovarian cancer incidence and mortality rates in postmenopausal women who had undergone hysterectomy.

Dr Liu Previews ASCO 2024 Lung Cancer Data

May 17th 2024

Stephen V. Liu, MD, discusses studies being presented at the 2024 ASCO Annual Meeting that may provide valuable insights into the management of NSCLC.

Dr Rajkumar Previews ASCO 2024 Data in Multiple Myeloma

May 17th 2024

S. Vincent Rajkumar, MD, discusses highly anticipated abstracts in multiple myeloma that will be presented at the 2024 ASCO Annual Meeting.

Novel ADCs Must Keep Up With Moving Targets in Metastatic Breast Cancer

August 22nd 2023

Barbara Pistilli, MD, discusses the mechanism of action of novel ADCs, the ways in which ADC targets in breast cancer can change over time, and how future research may pave the way for individualized treatment with this class of agents.

Herrera Spotlights Key Research Across Hematologic Malignancies From the 2023 ASCO Annual Meeting

August 1st 2023

Alex Herrera, MD, discussed key data from the SWOG S1826 trial and other important research in hematologic malignancies presented at the 2023 ASCO Annual Meeting.

Dr Hamilton on the Efficacy and Safety of Abemaciclib Plus ET in Elderly Patients With HR+/HER2- Breast Cancer

June 8th 2023

Erika P. Hamilton, MD, discusses the efficacy and safety of adjuvant abemaciclib plus endocrine therapy in patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer according to age.

Acalabrutinib and Zanubrutinib Produce Similar PFS in a Matching-Adjusted Indirect Comparison in R/R CLL

June 8th 2023

Acalabrutinib and zanubrutinib demonstrated similar investigator-assessed progression-free survival in patients with relapsed/refractory chronic lymphocytic leukemia.

Dr Rini on Sustained Survival Outcomes After Completion of Pembrolizumab and Axitinib in ccRCC

June 7th 2023

Brian I. Rini, MD, FASCO, discusses long-term survival outcomes in patients with advanced clear cell renal cell carcinoma who received frontline pembrolizumab and axitinib in the phase 3 KEYNOTE-426 trial.

Dr Tolaney on Final OS Data From the TROPiCS-02 Trial in HR+/HER2- Breast Cancer

June 7th 2023

Sara M. Tolaney, MD, MPH, discusses key data from a final overall survival analysis of the phase 3 TROPiCS-02 trial in hormone receptor–positive, HER2-negative breast cancer.

BL-B01D1 Demonstrates Antitumor Activity in EGFR+ NSCLC and Other Solid Tumors

June 7th 2023

The first-in-class EGFR x HER3 bispecific antibody-drug conjugate BL-B01D1 generated antitumor activity and safety in patients with advanced solid tumors, particularly EGFR-mutated and wild-type non–small cell lung cancer and nasopharyngeal carcinoma.

Sotorasib Provides Consistent Clinical Benefit Over Docetaxel in Key Co-Alteration Subgroups of KRAS G12C+ NSCLC

June 7th 2023

Sotorasib provided consistent benefit over docetaxel in the majority of key prespecified molecularly defined subsets of patients with pretreated KRAS G12C–mutated non–small cell lung cancer enrolled to the phase 3 CodeBreaK 200 trial.

Dabrafenib and Trametinib Plus Navitoclax Meets CR End Point in BRAF V600–mutant Metastatic Melanoma

June 7th 2023

The combination of dabrafenib and trametinib plus navitoclax generated responses and met the co-primary end point for complete response rate vs historical controls in patients with BRAF V600–mutant metastatic melanoma.

Epcoritamab Plus Rituximab/Lenalidomide Produces Responses in High-risk R/R Follicular Lymphoma

June 7th 2023

Treatment with the combination of epcoritamab, rituximab, and lenalidomide led to responses and durable remissions in patients with relapsed/refractory follicular lymphoma.

TTFields Plus SOC Improves OS in Metastatic NSCLC After Progression on Platinum-based Chemotherapy

June 6th 2023

The addition of tumor treating fields to standard-of-care immunotherapy or chemotherapy regimens elicited an improvement in overall survival vs SOC therapies alone in patients with metastatic non-small cell lung cancer following progression on or after platinum-based chemotherapy, according to data from the phase 3 LUNAR trial.